Intracellular Th Stock Performance
| ITCI Stock | USD 85.69 0.24 0.28% |
On a scale of 0 to 100, Intracellular holds a performance score of 9. The company retains a Market Volatility (i.e., Beta) of 0.79, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Intracellular's returns are expected to increase less than the market. However, during the bear market, the loss of holding Intracellular is expected to be smaller as well. Please check Intracellular's expected short fall, and the relationship between the value at risk and daily balance of power , to make a quick decision on whether Intracellular's current trending patterns will revert.
Risk-Adjusted Performance
9 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Intracellular Th are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Despite fairly uncertain fundamental indicators, Intracellular demonstrated solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.28 | Five Day Return 2.55 | Year To Date Return 21.56 | Ten Year Return 466.73 | All Time Return 471.27 |
1 | Disposition of 34396 shares by Sharon Mates of Intracellular at 12.73 subject to Rule 16b-3 | 08/30/2024 |
2 | Acquisition by Riggs Rory B of 246 shares of Intracellular at 73.17 subject to Rule 16b-3 | 09/30/2024 |
3 | ITCI Q3 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales | 10/30/2024 |
4 | Intra-Cellular Therapies Inc Q3 2024 Earnings Call Highlights Robust Sales Growth and ... | 10/31/2024 |
5 | Intra-Cellular Therapies Third Quarter 2024 Earnings Revenues Beat Expectations, EPS Lags | 11/01/2024 |
6 | Intra-Cellular Therapies Treatment Reduces Schizophrenia Relapse Risk 63 | 11/05/2024 |
7 | Intra-Cellular Therapies Inc Trading 3.56 percent Higher on Nov 6 | 11/06/2024 |
8 | Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress | 11/07/2024 |
9 | Disposition of 22869 shares by Halstead Michael of Intracellular at 23.94 subject to Rule 16b-3 | 11/12/2024 |
10 | FMR LLC Reduces Stake in Intra-Cellular Therapies Inc | 11/13/2024 |
11 | Intra-cellular therapies president sells 3.69 million in stock | 11/14/2024 |
12 | Acquisition by Van Nostrand Robert L of 1567 shares of Intracellular subject to Rule 16b-3 | 11/15/2024 |
| Begin Period Cash Flow | 150.4 M |
Intracellular |
Intracellular Relative Risk vs. Return Landscape
If you would invest 7,388 in Intracellular Th on August 27, 2024 and sell it today you would earn a total of 1,181 from holding Intracellular Th or generate 15.99% return on investment over 90 days. Intracellular Th is currently generating 0.2532% in daily expected returns and assumes 2.1097% risk (volatility on return distribution) over the 90 days horizon. In different words, 18% of stocks are less volatile than Intracellular, and 95% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Intracellular Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Intracellular's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Intracellular Th, and traders can use it to determine the average amount a Intracellular's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.12
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ITCI | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.11 actual daily | 18 82% of assets are more volatile |
Expected Return
| 0.25 actual daily | 4 96% of assets have higher returns |
Risk-Adjusted Return
| 0.12 actual daily | 9 91% of assets perform better |
Based on monthly moving average Intracellular is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Intracellular by adding it to a well-diversified portfolio.
Intracellular Fundamentals Growth
Intracellular Stock prices reflect investors' perceptions of the future prospects and financial health of Intracellular, and Intracellular fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Intracellular Stock performance.
| Return On Equity | -0.099 | ||||
| Return On Asset | -0.0745 | ||||
| Profit Margin | (0.14) % | ||||
| Operating Margin | (0.22) % | ||||
| Current Valuation | 8.1 B | ||||
| Shares Outstanding | 106.02 M | ||||
| Price To Earning | (6.56) X | ||||
| Price To Book | 7.94 X | ||||
| Price To Sales | 14.80 X | ||||
| Revenue | 464.37 M | ||||
| Gross Profit | 95.16 M | ||||
| EBITDA | (158.85 M) | ||||
| Net Income | (139.67 M) | ||||
| Cash And Equivalents | 628.74 M | ||||
| Cash Per Share | 6.64 X | ||||
| Total Debt | 16.94 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 9.81 X | ||||
| Book Value Per Share | 10.80 X | ||||
| Cash Flow From Operations | (124.2 M) | ||||
| Earnings Per Share | (0.87) X | ||||
| Market Capitalization | 9.08 B | ||||
| Total Asset | 728.29 M | ||||
| Retained Earnings | (1.62 B) | ||||
| Working Capital | 544.25 M | ||||
| Current Asset | 541.82 M | ||||
| Current Liabilities | 140.69 M | ||||
About Intracellular Performance
By evaluating Intracellular's fundamental ratios, stakeholders can gain valuable insights into Intracellular's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Intracellular has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Intracellular has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 125.98 | 227.33 | |
| Return On Tangible Assets | (0.19) | (0.20) | |
| Return On Capital Employed | (0.26) | (0.28) | |
| Return On Assets | (0.19) | (0.20) | |
| Return On Equity | (0.24) | (0.25) |
Things to note about Intracellular Th performance evaluation
Checking the ongoing alerts about Intracellular for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Intracellular Th help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the previous year's revenue of 464.37 M. Net Loss for the year was (139.67 M) with profit before overhead, payroll, taxes, and interest of 95.16 M. | |
| Intracellular Th currently holds about 628.74 M in cash with (124.2 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.64. | |
| Over 96.0% of the company shares are owned by institutional investors | |
| Latest headline from investing.com: Intra-cellular therapies president sells 3.69 million in stock |
- Analyzing Intracellular's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Intracellular's stock is overvalued or undervalued compared to its peers.
- Examining Intracellular's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Intracellular's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Intracellular's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Intracellular's stock. These opinions can provide insight into Intracellular's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Intracellular Stock analysis
When running Intracellular's price analysis, check to measure Intracellular's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intracellular is operating at the current time. Most of Intracellular's value examination focuses on studying past and present price action to predict the probability of Intracellular's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intracellular's price. Additionally, you may evaluate how the addition of Intracellular to your portfolios can decrease your overall portfolio volatility.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |